KVUE Kenvue Inc

$KVUE $KMB — EUROPEAN UNION APPROVES KIMBERLY-CLARK'S ACQUISITION OF KENVUE CONFIRMED REGULATORY DEVELOPMENT: The European Commission has approved Kimberly-Clark's acquisition of Kenvue, subject to divestiture commitments. KEY DETAILS: • Approval follows an antitrust review. • Kimberly-Clark agreed to divest its feminine hygiene brands throughout the European Economic Area. • Affected brands include Kotex, Camelia, Record and Lidie. MARKET TAKEAWAY: The approval removes an important regulatory obstacle to the transaction. However, this does not mean the acquisition has closed. Investors should monitor remaining closing conditions, the timing of the divestitures and any additional regulatory requirements. For merger-arbitrage investors, regulatory progress can reduce transaction uncertainty without eliminating completion risk.

$KVUE's EU review could expire Tuesday. Phase 1 runs 25 working days, not calendar days, so a Brussels holiday moves your closing date. That's most of why this one is hard to pin down.

$KVUE: moved out of Illinois? You can still claim in the $4.7M Skin360 settlement if you were in Illinois when you used the app, Dec 2019 to May 2023. Equal shares, sworn statement only. Claim by Nov 25. Open Class Actions.

$KVUE: about 6 weeks left on the $4.7M Skin360 settlement. Used Neutrogena's face-scan app in Illinois Dec 2019 to May 2023? No receipt or claim ID needed, file online, claim by Nov 25. Open Class Actions.

$KVUE holders: open class action over alleged face-geometry scans from Neutrogena's Skin360 app. $4.7M settlement, no proof needed to file, claim by Nov 25. Details on Open Class Actions.

$KVUE I obviously did not get the memo about the early dividend. I assume this has something to do with the sale of the company to Kimberly Clark?

$KVUE | Snapshot 📊⚡ • Business: Kenvue Inc. is the world’s largest pure-play consumer health company, operating high-margin brands in self-care, skin health, and essential wellness. • Financial Health & Pipeline: Stable defensive dividend yield with reliable free cash flow, capitalizing on steady global consumer demand across retail health categories. • Bias & Conviction: Bullish Channel Reversal | Moderate Conviction (Holding structural trendline support at $17.30 backed by 2027 call LEAPS sweep flow). 🎯 Key Levels: 🐂 Bull Trigger: $17.50 / $17.91 🚀 Targets: $19.50 / $21.00 / $22.00 🛡️ Support: $17.30 / $17.10 ⚠️ Risk: $15.00 / $14.00 🔥 Volume & Flow: • 🟢 Bullish long-term flow featuring $87.5K in 12/17/2027 $15C and $26.3K in 12/17/2027 $18C sweeps hitting the ask. #KVUE #consumerhealth #stocks #finance #hovdid

$KVUE catching a bid off its 50 DMA and about to retest this diagonal trendline. Will look good if it can get back inside the triangle.

$KVUE — Kenvue's recent analyses focused on technical indicators suggesting oversold conditions, alongside news of dividend declarations and ongoing business divestitures. Recent analyses for Kenvue (KVUE) have examined technical indicators such as SMAs, RSI, MFI, and MACD, which have largely pointed towards oversold conditions and bearish short-term momentum. The company's financial performance, including revenue and earnings growth, dividend yield, and profitability margins, has also been a subject of review. News flow has highlighted dividend declarations, product launches, and asset sales related to past acquisitions. Upside noted: Quarterly revenue growth of 3% year-over-year. Quarterly earnings growth of 8.5% year-over-year. Dividend Yield of approximately 4.71%. Risk noted: Trading below 50-day and 200-day SMAs. RSI and MFI indicating oversold territory. Negative MACD values suggesting bearish momentum.